Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Paige Rackliffe

Internal Medicine Richmond, VA Medical Doctor

NPI 1841277977 CMS profile 83773

3806 Mechanicsville Tpke, Richmond, VA 23223

Open in the dashboard

General payments

$6,458

392 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paige Rackliffe of Richmond, VA is reported in the CMS Open Payments database as having received $6,458 across 392 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,349 90
2024 General $1,774 96
2023 General $1,261 76
2022 General $1,084 76
2021 General $991 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paige Rackliffe
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Paige Rackliffe were reported at $1,349. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Paige Rackliffe Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $991 $135 $37–$521 $132
2022 $1,084 $141 $42–$496 $149
2023 $1,261 $149 $45–$519 $160
2024 $1,774 $154 $47–$537 $164
2025 $1,349 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,243 116 payments
  2. AstraZeneca Pharmaceuticals LP $921 26 payments
  3. Sumitomo Pharma America, Inc. $509 28 payments
  4. Amgen Inc. $472 34 payments
  5. Novo Nordisk Inc $342 20 payments
  6. Lilly USA, LLC $266 18 payments
  7. Abbott Laboratories $239 9 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $211 15 payments
  9. GlaxoSmithKline, LLC. $203 14 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $191 13 payments
  11. Other $1,861 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,458 392 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $685 64 payments
  2. GEMTESA $538 30 payments
  3. FASENRA $508 5 payments
  4. QULIPTA $494 51 payments
  5. FARXIGA $413 11 payments
  6. VRAYLAR $333 31 payments
  7. BREZTRI $327 8 payments
  8. REPATHA $257 21 payments
  9. Ozempic $255 15 payments
  10. RYBELSUS $227 14 payments
  11. Other $4,310 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 124 drugs

Part D claims

6,021

Median for Internal Medicine: 777

Drug cost

$336,723

Median for Internal Medicine: $73,373

Branded share of claims

17.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 70 $60,681
Eliquis Apixaban Brand 31 $32,413
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $26,939
Ozempic Semaglutide Brand 22 $26,132
Gemtesa Vibegron Brand 31 $25,072
Xarelto Rivaroxaban Brand 19 $24,186
Mounjaro Tirzepatide Brand 11 $21,619
Repatha Sureclick Evolocumab Brand 19 $20,506
Linzess Linaclotide Brand 17 $14,947
Januvia Sitagliptin Phosphate Brand 14 $11,528

The 10 drugs with the highest cost, of 124 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$199,372

Of which drugs: $60,026

Medicare patients

331

Average age 75

Services billed

7,989

265 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 46%
Ischemic heart disease 27%
Depression 24%
Osteoporosis 24%
Diabetes 20%
Chronic kidney disease 18%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 26 2,640 $54,183
Vaccine for influenza for injection into muscle 90662 Office 49 49 $4,009
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 56 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $288
$288 31 —
Leqembi
  • Eisai Inc. $106
$106 — —
UBRELVY
  • AbbVie, Inc. $101
$101 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $96
$96 — —
VRAYLAR
  • AbbVie, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record